Crinetics Pharmaceuticals, Inc. 8-K

What Happened Crinetics Pharmaceuticals, Inc. announced and furnished a press release on May 7, 2026 reporting its financial results for the period ended March 31, 2026. The announcement was made under Item 2.02 (Results of Operations and Financial Condition) of Form 8-K; the full press release is attached as Exhibit 99.1 to the filing.

Key Details

• Filing date: May 7, 2026; reporting period: quarter ended March 31, 2026.
• Press release attached as Exhibit 99.1 to the Current Report on Form 8-K.
• The Form 8-K states the information in the release is "furnished" (per General Instruction B.2) and therefore not deemed "filed" for Section 18 liability or automatically incorporated by reference into other filings.
• Report signed on behalf of the company by R. Scott Struthers, Ph.D., President and CEO.

Why It Matters This filing notifies investors that Crinetics has publicly released its latest quarterly financial results; investors should read the attached press release for specifics on revenue, operating results, cash position and any updated guidance. Note the company treated the release as furnished (not filed), which affects legal liability and incorporation into other SEC filings.